Results 11 to 20 of about 199,597 (317)

Tumour mutational burden: an overview for pathologists [PDF]

Pathology, 2022
Cancer immunotherapy holds great promise and has shown durable responses in many patients; however, these responses are not uniform in all patients or all tumour streams. There is an ongoing clinical need for objective diagnostic biomarkers to identify patients that will respond to immunotherapies.
Kenneth D. Doig, Andrew Fellowes, Prudence Scott, Stephen B. Fox   +3 more
openaire   +3 more sources

What is the burden of proof for tumor mutational burden in gliomas? [PDF]

Neuro-Oncology, 2020
Abstract The treatment of patients with a variety of solid tumors has benefitted from immune checkpoint inhibition targeting the anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis. The US Food and Drug Administration (FDA) granted accelerated approval of PD-1 inhibitor, pembrolizumab, for the treatment of ...
Mustafa Khasraw, Kyle M Walsh, Amy B Heimberger, David M Ashley   +3 more
openaire   +2 more sources

Mutational burden and immune recognition of gliomas

Current Opinion in Oncology, 2021
Purpose of review Recent evidence suggests high tumor mutational burden (TMB-H) as a predictor of response to immune checkpoint blockade (ICB) in cancer. However, results in TMB-H gliomas have been inconsistent. In this article, we discuss the main pathways leading to TMB-H in glioma and how these might affect immunotherapy ...
Prost, Diego, Bielle, Franck, Ligon, Keith, Touat, Mehdi   +3 more
openaire   +3 more sources

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker [PDF]

Cancer Cell, 2021
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T cells. To evade immune eradication, cancers exploit checkpoints that dampen T cell reactivity.
Denis L, Jardim, Aaron, Goodman, Debora, de Melo Gagliato, Razelle, Kurzrock   +3 more
openaire   +2 more sources

M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer

Frontiers in Oncology, 2021
BackgroundStudies have shown that N6-methyl adenosine (m6A) plays an important role in cancer progression; however, the underlying mechanism of m6A modification in tumor microenvironment (TME) cell infiltration of bladder cancer remains unclear.
Huili Zhu, Xiaocan Jia, Yuping Wang, Zhijuan Song, Nana Wang, Yongli Yang, Xuezhong Shi   +6 more
doaj   +1 more source

Cross-talk of four types of RNA modification proteins with adenosine reveals the landscape of multivariate prognostic patterns in breast cancer

Frontiers in Genetics, 2022
Background: Breast cancer (BC) is the most common malignant tumour, and its heterogeneity is one of its major characteristics. N6-methyladenosine (m6A), N1-methyladenosine (m1A), alternative polyadenylation (APA), and adenosine-to-inosine (A-to-I) RNA ...
Xuliren Wang, Fangdie Ye, Min Xiong, Bingqiu Xiu, Weiru Chi, Qi Zhang, Jingyan Xue, Ming Chen, Liyi Zhang, Jiong Wu, Jiong Wu, Yayun Chi   +11 more
doaj   +1 more source

Integrated machine learning and bioinformatic analyses used to construct a copper-induced cell death-related classifier for prognosis and immunotherapeutic response of hepatocellular carcinoma patients

Frontiers in Pharmacology, 2023
Background: Copper as phytonutrient has powerful activity against health diseases. A newly discovered mechanism of cell death that affects energy metabolism by copper (“cuproptosis”) can induce multiple cuproptosis-related genes. Hepatocellular carcinoma
Shuai Zhao, Shuxian Chen, Wangrui Liu, Shiyin Wei, Xinrui Wu, Dan Cui, Lifeng Jiang, Siyu Chen, Jian Wang   +8 more
doaj   +1 more source

Bias and Inconsistency in the Estimation of Tumour Mutation Burden

BMC Cancer, 2022
Abstract Background: Tumour mutation burden (TMB), defined as the number of somatic mutations per megabase within the sequenced region in the tumour sample, has been used as a biomarker for predicting response to immune therapy. Several studies have been conducted to assess the utility of TMB for various cancer types; however, methods to ...
Mohammad A. Makrooni, Brian O’Sullivan, Cathal Seoighe   +2 more
openaire   +3 more sources

Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach Adenocarcinoma

Frontiers in Cell and Developmental Biology, 2022
Background: Stomach adenocarcinoma (STAD) is one of the most common tumors. Tumor mutation burden (TMB) has been linked to immunotherapy response. We wanted to see if there was any link between TMB and cancer prognosis.Methods: The Cancer Genome Atlas ...
Min Fu, Yongbiao Huang, Xiaohong Peng, Xiaoyu Li, Na Luo, Wenjun Zhu, Feng Yang, Ziqi Chen, Shengling Ma, Yuanyuan Zhang, Qianxia Li, Guangyuan Hu   +11 more
doaj   +1 more source

Tumor mutation burden: from comprehensive mutational screening to the clinic [PDF]

Cancer Cell International, 2019
The recent advent of immunomodulatory therapies into the clinic has demanded the identification of innovative predictive biomarkers to identify patients most likely to respond to immunotherapy and support the design of tailored clinical trials. Current molecular testing for selection of patients with gastrointestinal or pulmonary carcinomas relies on ...
Galuppini F., Dal Pozzo C. A., Deckert J., Loupakis F., Fassan M., Baffa R.   +5 more
openaire   +4 more sources